Single-cell analysis

Advaita Bio awarded $1.7 million NIH study to pioneer platform for the analysis of single-cell data

Retrieved on: 
Tuesday, January 30, 2024
ANN, Research, Single-cell analysis, Life, Collection, RNA-Seq, Knowledge, Science, Computer, Gene, Advaita Vedanta, Single-nucleotide polymorphism, Principal investigator, Software, NIH, Auburn University, DVM, Protein, Doctor of Philosophy, Bangladesh Technical Education Board

ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data. AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types. This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.

Key Points: 
  • ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data.
  • AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types.
  • This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.
  • Advaita's Life Scientist and Principal Investigator, Cristiana Iosef, DVM, PhD, explains, "The world of single cell analysis is currently a jungle.

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

Retrieved on: 
Tuesday, January 23, 2024
NGS, Library, Health, DNA, Multiomics, BDX, Single-cell analysis, Disease, Automation, Cell, Computer data storage

FRANKLIN LAKES, N.J., Jan. 23, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

Key Points: 
  • The combination will automate steps, including pipetting and thermal cycling, to produce DNA samples or "libraries" that are ready for genetic sequencing.
  • In single-cell multiomics experiments, constructing libraries of fragmented genetic information that can be read by sequencing instruments is an essential first step before next-generation sequencing (NGS) can be performed and insights from cells can be gathered.
  • As more researchers adopt the rapidly evolving and important approach of single-cell multiomics, we believe that having automated solutions for high-throughput experiments will serve to accelerate their potentially life-changing discoveries."
  • The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications will be developed and released in phases starting in 2024.

United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive the Development of Personalized Medicine

Retrieved on: 
Tuesday, January 16, 2024
Artificial intelligence, Research, Proteomics, Single-cell analysis, Genomics, Software, NIH, Machine learning, Data analysis, Single cell sequencing, Bangladesh Technical Education Board, Growth, Fine chemical

DUBLIN, Jan. 16, 2024 /PRNewswire/ -- The "Growth Opportunities in Single Cell Genomics and Proteomics in the United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 16, 2024 /PRNewswire/ -- The "Growth Opportunities in Single Cell Genomics and Proteomics in the United States" report has been added to ResearchAndMarkets.com's offering.
  • It began as a niche, specialized technology with few companies offering solutions, which then became commonly used in academia.
  • The United States represents about 60% of the total market and is on track to increase about 12% to 16% annually.
  • These novel tools encourage the development of software and data analysis solutions to help researchers interpret data.

One Biosciences Partners With AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease

Retrieved on: 
Friday, November 10, 2023
Research, Assistance Publique–Hôpitaux de Paris, Transplant, AP-HP, Kidney disease, Disease, AI, A.I, Patient, Medicine, Creative Biolabs, Heart, Partnership, Syndrome, Biomarker, Sorbonne University, Hospital, Silla, Curie Institute (Paris), Single-cell analysis, Pharmaceutical industry, News

PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.

Key Points: 
  • PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.
  • A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
  • One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
  • This is an important milestone, and I'd like to thank our partners for their commitment," said Hedi Ben Brahim, CEO of One Biosciences.

Almaden Genomics’ g.nome™ Further Enhances Single-Cell Analysis

Retrieved on: 
Wednesday, December 13, 2023
Technology, Genetics, Health Technology, Professional Services, Software, Stem Cells, Biotechnology, Data Analytics, Health, Data Management, Beth Singler, HTML, RNA-Seq, QC, Genomics, Gene expression, UMAP, Single-cell analysis, Cell, Gene expression profiling

Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.

Key Points: 
  • Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.
  • A cloud-native platform designed for high-throughput sequencing data analysis, g.nome now includes features for alignment and quantification of gene expression per cell, Seurat clustering analysis, reference-based cell-type annotation, and built-in parallelization.
  • The g.nome platform also provides a powerful, yet flexible system for single cell analysis with a workflow builder, quick and easy plug-n-play workflows, and interactive visualizations.
  • Single-cell analysis was added to g.nome earlier this year, enabling understanding of cellular diversity and disease mechanisms on a much more granular level.

BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer

Retrieved on: 
Wednesday, November 29, 2023
Other Health, Research, General Health, Oncology, Technology, Genetics, Science, Cardiology, Neurology, Other Technology, Other Science, Health, Pacific Biosciences, Molecular biology, Genomics, Multimedia, Doctor of Philosophy, Marketing, University, Cancer, Growth, CCO, Single-cell analysis, Management, Illumina

BioSkryb Genomics , a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.

Key Points: 
  • BioSkryb Genomics , a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.
  • Dr. Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence.
  • View the full release here: https://www.businesswire.com/news/home/20231129687097/en/
    BioSkryb has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.
  • (Photo: Business Wire)
    Dr. Laxman joins BioSkryb from 10x Genomics, where he served as the President and General Manager, APAC.

Deepcell Garners Industry Recognition for Disruptive AI-Driven Approach to Single Cell Morphology Analysis

Retrieved on: 
Tuesday, November 14, 2023
Technology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Stem Cells, Oncology, Other Science, Research, Software, Infectious Diseases, Genetics, Science, Data Management, Axon, Cell biology, Deep learning, Entrepreneurship, Artificial intelligence, Cell, Intelligence, Biomedical Research, Biotechnology, Developmental biology, EST, Society, AMP, Live single-cell imaging, News, Mary K. Estes, Single-cell analysis, Microscope, Boston

Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today shared the news of two significant industry recognitions as it prepares for upcoming scientific meetings.
  • Earlier this year, Deepcell launched the REM-I platform , a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.
  • By bringing together single cell imaging, sorting, and high-dimensional analysis, the REM-I platform catalyzes new methods of discovery in a wide range of fields including cancer biology, developmental biology, stem cell biology, gene therapy and functional screening, among others.
  • Deepcell’s REM-I platform was selected as "Cell Imaging Product of the Year," one of only four breakthrough innovations in the field of cell biology, in the third annual BioTech Breakthrough Awards.

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

Retrieved on: 
Tuesday, November 7, 2023
Genomics, RNA, TCR, CRISPR, VDJ, Certification, Drug development, San Francisco Bay Area, NGS, ATAC, 10x Genomics, Single-cell analysis, T cell, Gene expression, ATAC-seq, Gene expression profiling, Fine chemical, Vaccine

FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.

Key Points: 
  • FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.
  • Combining MedGenome's expertise in single cell data analysis promises to deliver groundbreaking insights into complex and rare diseases.
  • The 10x Genomics certification highlights MedGenome's expertise in offering single-cell sequencing tools to help researchers accelerate their genomic studies.
  • MedGenome is positioned as the top genomics research service provider in the San Francisco Bay Area.

OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study

Retrieved on: 
Monday, November 6, 2023
Genomics, Owkin, Data, B cell, MOSAIC, Neoplasm, Single-cell analysis, Chromium, Cancer, Patient, Deterministic Barcoding in Tissue for Spatial Omics Sequencing, Medical imaging, Visium Asset Management

PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.

Key Points: 
  • PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.
  • I am really excited that the MOSAIC study will use the 10x Visium and Chromium platforms to generate spatial and single-cell transcriptomics for thousands of cancer patients.
  • Jim Wilbur, Chief Commercial Officer at 10x Genomics, said, "We're thrilled to have our leading technologies take on such an important, enabling role in the MOSAIC study.
  • With the addition of 10x, the distinguished team of MOSAIC researchers will have access to world-class single cell and spatial tools.

BioSkryb Genomics to Present New Single-Cell Multiomic Data at ASHG 2023

Retrieved on: 
Monday, October 30, 2023
Research, Technology, Other Technology, Health Technology, Other Health, General Health, Health, Science, Oncology, Other Science, ASHG, Acute leukemia, Genomics, Mosaic, PIK3CA, Breast cancer, Annual general meeting, Single-cell analysis, B-ALL, Medical imaging, Vaccine, D.C

We look forward to highlighting these recent accomplishments amongst our industry colleagues.”

Key Points: 
  • We look forward to highlighting these recent accomplishments amongst our industry colleagues.”
    BioSkryb’s presentation schedule at ASHG 2023 is as follows:
    Description: Pairing Sony SH800 sorting with ResolveOME™ multiomic profiling unlocked the ability to discern somatic mosaicism and tumor evolution.
  • Heterogeneous PIK3CA mutations, copy number alterations, and transcriptional cell states were revealed in single breast cancer cells.
  • Single nucleus sorting in primary neurons, murine brain, and cell lines enabled nuclear transcriptional profiling and quantitation of genomic copy number variation.
  • It also identified a potential genotype-phenotype association between two deletions in chromosome 6 and a more stem-like state.